Statistical justification of expansion cohorts in phase 1 cancer trials
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31577
Abstract: Phase I cancer trials increasingly incorporate dose‐expansion cohorts (DECs), reflecting a growing demand to acquire more information about investigational drugs. Protocols commonly fail to provide a sample‐size justification or analysis plan for the DEC. In… read more here.
Keywords: cancer; phase cancer; expansion cohorts; cancer trials ... See more keywords
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.515
Abstract: 515Background: Tolerability and efficacy of CaboNivo and CaboNivoIpi were demonstrated in the initial phase I cohort, prompting longer follow-up and the addition of expansion cohorts to further evaluate both combinations Methods: Phase I cohort had… read more here.
Keywords: cabo 40mg; carcinoma; expansion cohorts; muc ... See more keywords